Dachaigh › Ailseas Esophageach › Texas › Houston
Sgrùdaidhean clionaigeach Ailseas Esophageach ann an Houston, TX
Tha 36 sgrùdaidhean airson Ailseas Esophageach a’ lorg phàirtichean aig làraichean ann agus timcheall air Houston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A’ fastadhÌre 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
A’ fastadhÌre 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
A’ fastadhÌre 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
A’ fastadhÌre 2
- MD Anderson Cancer Center (Data Collection Only), Houston
Pan-tumor MRD Study
A’ fastadhSgrùdadh amharc
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
A’ fastadhÌre 1
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A’ fastadhÌre 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A’ fastadhÌre 1
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A’ fastadhÌre 3
- Research Site, Houston
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
A’ fastadhÌre 1/2
- University of Texas MD Anderson Cancer Center ( Site 8920), Houston
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
A’ fastadhÌre 1/2
- University of Texas MD Anderson Cancer Center ( Site 6920), Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Oncology Consultants, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A’ fastadhÌre 2
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A’ fastadhÌre 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
A’ fastadhÌre 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
A’ fastadhSgrùdadh amharc
- M D Anderson Cancer Center, Houston
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- MD Anderson Cancer Center, Houston
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
A’ fastadhÌre 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
A’ fastadhFàilte do shaor-thoilich fhallain
- M D Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
A’ fastadhÌre 2
- M D Anderson Cancer Center, Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
A’ fastadhSgrùdadh amharc
- Baylor College of Medicine, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
A’ fastadhSgrùdadh amharc
- Md Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
A’ fastadhÌre 1
- Baylor St. Luke's Medical Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1
- Oncology Consultants, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
A’ fastadhÌre 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Houston
Distribution of Lymph Node Metastases in Esophageal Carcinoma
A’ fastadhSgrùdadh amharc
- MD Anderson Cancer Center, Houston
Sgrùdaidhean Ailseas Esophageach ann am bailtean eile
- Boston, MA23 sgrùdaidhean
- New York City, NY22 sgrùdaidhean
- Nashville, TN19 sgrùdaidhean
- St. Louis, MO17 sgrùdaidhean
- Pittsburgh, PA15 sgrùdaidhean
- Los Angeles, CA15 sgrùdaidhean
- Baldwin Park, CA14 sgrùdaidhean
- Grand Rapids, MI14 sgrùdaidhean
- Philadelphia, PA13 sgrùdaidhean
- San Antonio, TX12 sgrùdaidhean
- Rochester, MN11 sgrùdadh
- Arlington, VA11 sgrùdadh
Sgrùdaidhean eile ann an Houston
- Aillse Sgamhain Neo-chealla-beag145 sgrùdaidhean
- Aillse a' bhroilleach126 sgrùdaidhean
- Aillse (gach seòrsa)121 sgrùdaidhean
- Ailse metastatach104 sgrùdaidhean
- Aillse colorectal102 sgrùdaidhean
- Cancer Ovarian89 sgrùdaidhean
- Leukemia myeloid geur85 sgrùdaidhean
- Ailseachadh nan Sgamhan78 sgrùdaidhean
- Aillse Prostata76 sgrùdaidhean
- Ailse Endometrial68 sgrùdaidhean
- Cancer Pancreatic61 sgrùdaidhean
- Melanoma59 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.